Zions Bancorporation N.A. Purchases 14,762 Shares of Haemonetics Co. (NYSE:HAE)

Zions Bancorporation N.A. grew its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 56.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 40,996 shares of the medical instruments supplier's stock after buying an additional 14,762 shares during the quarter. Zions Bancorporation N.A. owned approximately 0.08% of Haemonetics worth $3,201,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Arizona State Retirement System grew its position in shares of Haemonetics by 1.2% during the 4th quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier's stock worth $1,160,000 after buying an additional 181 shares during the period. Parkside Financial Bank & Trust grew its holdings in Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after acquiring an additional 240 shares during the period. HighTower Advisors LLC grew its holdings in Haemonetics by 7.8% during the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock worth $262,000 after acquiring an additional 244 shares during the period. Xponance Inc. lifted its stake in shares of Haemonetics by 5.9% in the 4th quarter. Xponance Inc. now owns 7,246 shares of the medical instruments supplier's stock valued at $566,000 after purchasing an additional 404 shares during the period. Finally, Isthmus Partners LLC lifted its stake in shares of Haemonetics by 1.1% in the 4th quarter. Isthmus Partners LLC now owns 40,220 shares of the medical instruments supplier's stock valued at $3,140,000 after purchasing an additional 450 shares during the period. 99.67% of the stock is owned by institutional investors.

Remove Ads

Haemonetics Stock Down 1.8 %

Shares of NYSE:HAE traded down $1.18 during mid-day trading on Friday, reaching $63.03. 553,424 shares of the stock were exchanged, compared to its average volume of 666,316. The company has a market cap of $3.17 billion, a P/E ratio of 24.81, a P/E/G ratio of 1.11 and a beta of 0.43. The stock's 50 day simple moving average is $66.05 and its 200-day simple moving average is $74.68. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a one year low of $58.80 and a one year high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, equities research analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on HAE shares. JPMorgan Chase & Co. initiated coverage on Haemonetics in a report on Friday, December 6th. They issued an "overweight" rating and a $116.00 price objective for the company. JMP Securities cut their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research report on Friday, February 7th. Needham & Company LLC decreased their price objective on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a report on Tuesday, March 18th. Raymond James reiterated a "strong-buy" rating and issued a $115.00 target price (down from $120.00) on shares of Haemonetics in a report on Friday, February 7th. Finally, Bank of America lowered shares of Haemonetics from a "neutral" rating to an "underperform" rating and decreased their price target for the company from $95.00 to $68.00 in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $101.22.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.